This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Study participants were randomly assigned 1:1 to receive Zepbound (10mg or 15mg; maximum tolerated dose) or placebo injected subcutaneously once weekly. The primary endpoint was the change from ...

The FDA approved Zepbound to treat moderate to severe OSA in adults with obesity. The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to ...

This order relates to certain FDA-approved Mounjaro and Zepbound products. The Mounjaro products are pre-filled single-dose pens (2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL ...

Meanwhile, people on low-dose tirzepatide (5 mg) lost weight, but not nearly as much as those on 10 mg and 15 mg ... tirzepatide for Mounjaro and Zepbound). It's not likely that lower doses ...

Provepharm said it pulled lot No. 24020027 with December 2025 of Phenylephrine hydrochloride Injection, USP, 10 mg/mL after ...

The study included five dose cohorts (2 mg, 5 mg, 10 mg, 20 mg, and 40 mg) of 40 patients with obesity under fasting conditions, with results demonstrating dose-proportional pharmacokinetics (PK), a ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...